ONVO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ONVO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Organovo Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.50 Mil. Organovo Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.00 Mil. Organovo Holdings's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $6.18 Mil. Organovo Holdings's debt to equity for the quarter that ended in Dec. 2023 was 0.24.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Organovo Holdings's Debt-to-Equity or its related term are showing as below:
During the past 12 years, the highest Debt-to-Equity Ratio of Organovo Holdings was 0.24. The lowest was 0.07. And the median was 0.12.
The historical data trend for Organovo Holdings's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Organovo Holdings Annual Data | |||||||||||||||||||||
Trend | Mar14 | Mar15 | Mar16 | Mar17 | Mar18 | Mar19 | Mar20 | Mar21 | Mar22 | Mar23 | |||||||||||
Debt-to-Equity | Get a 7-Day Free Trial | - | - | - | 0.07 | 0.12 |
Organovo Holdings Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Debt-to-Equity | Get a 7-Day Free Trial | 0.09 | 0.12 | 0.15 | 0.19 | 0.24 |
For the Biotechnology subindustry, Organovo Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Organovo Holdings's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Organovo Holdings's Debt-to-Equity falls into.
Debt to Equity measures the financial leverage a company has.
Organovo Holdings's Debt to Equity Ratio for the fiscal year that ended in Mar. 2023 is calculated as
Debt to Equity | = | Total Debt | / | Total Stockholders Equity | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Total Stockholders Equity | |
= | (0.492 | + | 1.313) | / | 15.329 | |
= | 0.12 |
Organovo Holdings's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as
Debt to Equity | = | Total Debt | / | Total Stockholders Equity | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Total Stockholders Equity | |
= | (0.502 | + | 0.999) | / | 6.182 | |
= | 0.24 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Organovo Holdings (NAS:ONVO) Debt-to-Equity Explanation
In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.
Be Aware
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Thank you for viewing the detailed overview of Organovo Holdings's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
David Gobel | director | 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075 |
Vaidehi Joshi | director | C/O ORGANOVO HOLDINGS, INC., 11555 SORRENTO VALLEY ROAD, SUITE 100, SAN DIEGO CA 92121 |
Alison Tjosvold Milhous | director | 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075 |
Adam K Stern | director | STERN AEGIS VENTURES, 810 7TH AVENUE 22ND FLOOR, NEW YORK NY 10019 |
Thomas Hess | officer: President, CFO and PFO | 366 MADISON AVE. 12TH FLOOR, NEW YORK NY 10017 |
Douglas Jay Cohen | director | 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075 |
Thomas E Jurgensen | officer: General Counsel & Secretary | 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075 |
Jeffrey N. Miner | officer: Chief Scientific Officer | 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075 |
Chris Heberlig | officer: President and CFO | C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11 |
Keith Murphy | director, officer: Executive Chairman | 6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121 |
Steven George Hughes | officer: Chief Medical Officer | 6275 NANCY RIDGE DRIVE, SAN DIEGO CA 92121 |
Carolyn Beaver | director | 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121 |
David Shapiro | director | C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES ST., NEW YORK NY 10013 |
Presnell Sharon Collins | officer: EVP, Research & Development | 6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121 |
Taylor Crouch | director, officer: CEO & President | 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075 |
From GuruFocus
By Graham Griffin Graham Griffin • 03-11-2021
By GlobeNewswire GlobeNewswire • 09-17-2021
By sperokesalga sperokesalga • 03-21-2023
By GF Value GF Value • 03-30-2021
By Marketwired Marketwired • 03-23-2020
By Business Wire Business Wire • 03-28-2020
By GuruFocusNews GuruFocusNews • 05-17-2022
By Marketwired Marketwired • 03-31-2020
By Business Wire Business Wire • 04-08-2020
By Marketwired Marketwired • 09-17-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.